Nathalle Silvestre

Title: Nathalle Silvestre: Innovator in Poxvirus Technology

Introduction

Nathalle Silvestre is a prominent inventor based in Ergersheim, France. He has made significant contributions to the field of gene therapy, particularly through his innovative work on poxviral particles. His research focuses on developing targeted therapies that can specifically recognize and bind to cancer cells.

Latest Patents

Nathalle Silvestre holds a patent for a poxvirus with targeted infection specificity. The patent describes a poxviral particle that has a heterologous ligand moiety on its surface, allowing it to specifically recognize and bind to an anti-ligand molecule located on the surface of target cells. This invention is particularly relevant for therapeutic and prophylactic applications, especially in the context of gene therapy aimed at preventing or treating cancer in mammals.

Career Highlights

Throughout his career, Nathalle Silvestre has been associated with Transgene S.A., a company known for its pioneering work in the field of immunotherapy and gene therapy. His innovative approach to poxvirus technology has positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Nathalle has collaborated with notable colleagues such as Jean Marc Balloul and Stephane Paul. These collaborations have further enhanced the research and development efforts in the field of targeted therapies.

Conclusion

Nathalle Silvestre's work in poxvirus technology represents a significant advancement in gene therapy, particularly for cancer treatment. His innovative patent and collaborations highlight his commitment to improving therapeutic options for patients.